JonathanZagerMD

Melanoma, Surgical Oncology (Other than Breast)

Chief Academic Officer Designated Institutional Official Director of Regional Therapies Senior Member, Department of Cutaneous Oncology, Moffitt Cancer Center Professor of Surgery and Chair of the Department of Oncologic Sciences, USF-Morsani College of Medicine.

Request Appointment

Overview of Dr. Zager

Dr. Jonathan Zager is a surgical oncologist, Director of Regional Therapies and Senior Member in the Cutaneous Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa FL. He is the Chief Academic Officer at Moffitt Cancer Center as well as the Designated Institutional Official (ACGME). He is a professor of surgery and Chair of the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. He received his medical degree from Tel Aviv University Sackler and has been in practice 20 years. He specializes in melanoma and surgical oncology (other than breast) and is experienced in the multidisciplinary management of melanoma, Merkel cell carcinoma and other complicated soft tissue and cutaneous malignancies. Dr. Zager has published nearly 300 peer reviewed articles edited textbooks and textbook chapters. He has given over 350 talks national and internationally on melanoma, Merkel cell carcinoma, basal and squamous cell carcinomas including topics such as regional therapies and the management of complex advanced and recurrent disease.

Office
10920 North McKinley Drive
4123
Tampa, FL 33612
Book by Phone+1(361) 322-9685

Fax+1 813-745-5725

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2004 - 2006
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 2001 - 2004
Memorial Sloan Kettering Cancer CenterFellowship, Hepatobiliary Surgery, 1999 - 2001
Zucker School of Medicine at Hofstra/NorthwellResidency, Surgery, 1997 - 1999
Tel Aviv University SacklerClass of 1997

Certifications & Licensure

GA State Medical License 2014 - 2026
TX State Medical License 2004 - 2026
FL State Medical License 2006 - 2025
NY State Medical License 1998 - 2005
American Board of Surgery Surgery

Awards, Honors, & Recognition

Best Doctors in America Best Doctors
Americas Top Surgeons
Most Compassionate Doctor American Registry
Patients Choice Award Patients Choice
Whos Who in Medicine and Healthcare Marquis Whos Who
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Completed
Phase 1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Completed
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
Active, not recruiting
Not Applicable
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
No longer available
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study Start of enrollment: 2013 Jan 24
Completed
Phase 1
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Completed
Phase 1
Biomarker Correlates of Hypoxia in Metastatic Melanoma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma Start of enrollment: 2016 Feb 01
Completed
Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients Start of enrollment: 2018 Sep 20
Recruiting
Phase 3
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients Start of enrollment: 2020 Dec 22
Active, not recruiting
Phase 2
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Oct 22
Recruiting
Phase 1
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Start of enrollment: 2022 Jun 10
Active, not recruiting
Phase 3
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

100 citations
Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Met...
Michael S. Hughes, Jonathan S. Zager, Mark B. Faries, H. Richard Alexander, Richard E. Royal
Annals of Surgical Oncology. 2016-04-01
59 citations
Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Ioannis Karydis, Alexandra Gangi, Matthew Wheater, Junsung Choi, Iain Wilson
Journal of Surgical Oncology. 2018-05-01
43 citations
Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.
Meghan R. Forster, Omar M. Rashid, Matthew C. Perez, Junsung Choi, Tariq Chaudhry
Journal of Surgical Oncology. 2014-04-01

Journal Articles

Microsatellitosis in Patients with Melanoma
Richard L White, Mark B Faries, Stanley P Leong, Andrew J Sinnamon, Dale Han, Jane L Messina, Barbara A Pockaj, Giorgos C Karakousis, Edmund K Bartlett, John T Vetto, ..., Annals of Surgical Oncology
Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?
C Wayne Cruse, Vernon K Sondak, Ricardo J Gonzalez, Daniel E Oliver, Jane L Messina, Louis B Harrison, Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology
Resection Margins in Merkel Cell Carcinoma: Is a 1-Cm Margin Wide Enough?
Daniel E Oliver, Vernon K Sondak, C Wayne Cruse, Louis B Harrison, Ricardo J Gonzalez, Amod A Sarnaik, Jonathan S Zager, Jane L Messina, Annals of Surgical Oncology
Join now to see all

Press Mentions

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma PatientsAugust 27th, 2024
Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal SurgeriesMarch 2nd, 2022
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
Join now to see all

Committees

Chair, Disease Site Working Group - Melanoma/ Sarcoma. SSO

Professional Memberships

Society of Surgical Oncology - SSO
Member
American College of Surgeons - ACS
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PPO
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment